Source: International Congress 2016 – Prognostic variables in lung cancer II
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Luis Mur (Aberystwyth, United Kingdom), Adian Mironas, Simon Cameron, Keiron O’Shea, Paul Lewis, Luis Mur, Keir Lewis. Exploiting metabolomic approaches to aid in the diagnosis of lung cancer. Eur Respir J 2016; 48: Suppl. 60, 2871

Member's Comments

No comment yet.

Related content which might interest you: Metabolic modification as a potential therapeutics approach in lung cancer Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP) Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy Year: 2013 Metabolomic profiling of clinical sputum samples reveals novel biomarkers for the early identification of lung cancer patients Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Potential lung cancer biomarkers from bronchoalveolar lavage fluid using metabolomics approaches Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Novel survey tool used to assess priorities of lung cancer patients and carers Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Optimization of cfDNA routine use for NSCLC genomic alteration analysis Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016 Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Determining genomic rearrangements in clinical lung specimens for assessment of metastatic disease, actionable targets and disease monitoring Source: International Congress 2016 – New genomic targets in pulmonary disease Year: 2016 Development of an invasive 3D lung tumor model for oncological research Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Large-scale quantitative proteomic analysis identifies pathways in COPD-associated lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Molecular profiling of lung squamous carcinogenesis Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Reducing delays in lung cancer diagnostic pathways to improve patient experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Population’s understanding and degree of participation of a screening lung cancer programme Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013